Treatment toxicity and efficacy in 90 patients with lymphoma who had an HIV score of 2-3, according to HAART era
Patients with HIV score of 2-3 . | Before HAART . | . | After HAART . | . | ||
|---|---|---|---|---|---|---|
| . | Ld-CHOP . | VS . | Ld-CHOP . | VS . | ||
| Toxicity grade 3-4, no. (%) | ||||||
| Platelets | 9 (23) | 4 (12) | 2 (20) | 1 (11) | ||
| Leukocytes | 17 (44)* | 4 (12)* | 3 (30) | 1 (11) | ||
| Infection | 10 (26) | 3 (9) | 2 (20) | 4 (44) | ||
| Response to chemotherapy | ||||||
| CR/Cru, no. (%) | 8 (21) | 2 (6) | 3 (30) | 1 (11) | ||
| 3-y OS, % (95% Cl) | 3 (0, 7) | 2 (0, 10) | 42 (6, 79) | 0 | ||
| 3-y EFS, % (95% Cl) | 2 (0, 7) | 0 | 28 (0, 62) | 0 | ||
| 3-y DFS, % (95% Cl) | 12 (0, 35) | 0 | 66 (13, 100) | 0 | ||
Patients with HIV score of 2-3 . | Before HAART . | . | After HAART . | . | ||
|---|---|---|---|---|---|---|
| . | Ld-CHOP . | VS . | Ld-CHOP . | VS . | ||
| Toxicity grade 3-4, no. (%) | ||||||
| Platelets | 9 (23) | 4 (12) | 2 (20) | 1 (11) | ||
| Leukocytes | 17 (44)* | 4 (12)* | 3 (30) | 1 (11) | ||
| Infection | 10 (26) | 3 (9) | 2 (20) | 4 (44) | ||
| Response to chemotherapy | ||||||
| CR/Cru, no. (%) | 8 (21) | 2 (6) | 3 (30) | 1 (11) | ||
| 3-y OS, % (95% Cl) | 3 (0, 7) | 2 (0, 10) | 42 (6, 79) | 0 | ||
| 3-y EFS, % (95% Cl) | 2 (0, 7) | 0 | 28 (0, 62) | 0 | ||
| 3-y DFS, % (95% Cl) | 12 (0, 35) | 0 | 66 (13, 100) | 0 | ||
For pre-HAART patients on Ld-CHOP, n = 39; on VS, n = 32. For post-HAART patients on Ld-CHOP, n = 10; on VS, n = 38.
Comparison between treatment arms within the HAART era: P ≤ .01.